scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Roche has another half-dozen phase 3 trials on the go with tiragolumab in other NSCLC settings ...

and supports the potential therapeutic benefit of inhibiting the TIGIT pathway.” “I was also encouraged by the consistency of meaningful improvements across other outcome measures for the ...

The company identified PVRIG and TIGIT as immune checkpoints in the DNAM axis, an important signaling pathway in T- and NK-cell function, which led to the discovery and development of novel ...

A viable strategy could be the use of combination immunotherapies targeting multiple immunosuppressive pathways to fully activate T cells and enhance response rates.